

Appendix 1. Coding of Procedures, Treatments, and Complications Analyzed

	CPT	ICD9
Procedures		
Oophorectomy and/or hysterectomy and/or cytoreduction	49203, 49204, 49205, 58150, 58152, 58180, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290, 58291, 58292, 58293, 58294, 56303, 56307, 56308, 58541, 58542, 58543, 58544, 58548, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573 58661, 58720 58920, 58925, 58940, 58943, 58950, 58951, 58952, 58953, 58954, 58956, 58957, 58958, 58960, 58594	65.22, 65.24, 65.25, 65.29, 65.3, 65.31, 65.39, 65.4, 65.41, 65.49, 65.5, 65.51, 65.52, 65.53, 65.6, 65.61, 65.62, 65.63, 65.64, 68.3, 68.31, 68.39, 68.4, 68.41, 68.49, 68.5, 68.51, 68.59, 68.6, 68.61, 68.69, 68.7, 68.71, 68.79 68.8, 68.9, 70.32
Chemotherapy		
Intraperitoneal chemotherapy	96445, 96446	54.97
Toxicity		
<i>Electrolyte disorders</i>		
Hyponatremia		276.1
Hypokalemia		276.8
Electrolyte disorder NOS		276.9
Infusion of electrolytes		99.18
Dehydration/hypovolemia		276.5, 276.50, 276.51, 276.52
Hypomagnesemia		275.2
<i>Constitutional Symptoms</i>		
Malaise/fatigue/failure to thrive		780.79, 783.41,
Syncope		780.2
Dizziness		780.4
Dysequilibrium		
Adverse effects of systemic treatment		E933.1
Complications of treatment		

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. Obstet Gynecol 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Page 1 of 7

Signs or symptoms with or without chief complaint	
<i>Gastrointestinal Disorders</i>	
Nausea and emesis	787, 787.0, 787.01, 787.02, 787.03, 536.2, 578.0
Diarrhea	009.2, 009.3, 564.5, 787.91
Constipation	564.0, 564.00, 564.01, 564.02, 564.09
Gastroenteritis/enteritis	009.0, 009.1, 558, 558.2, 558.9
<i>Malnutrition</i>	
Failure to thrive	783.7
Abnormal weight loss/underweight	783.2, 783.21, 783.22
Cachexia/Anorexia	799.4, 783.0
Malnutrition	263, 263.0, 263.1, 263.8, 263.9
Parenteral nutrition/TPN/PPN	99.15
Nutritional/metabolic disorder	
<i>Anemia and Red Cell Transfusion</i>	
Iron Deficiency anemia	280, 280.0, 280.1, 280.8, 280.9
Other deficiency anemia	281, 281.0, 281.1, 281.2, 281.3, 281.4, 281.8, 281.9
Aplastic anemia	284, 284.1 284.2, 284.8, 284.81, 284.89,
Other and unspecified anemia	285, 285.0, 285.1, 285.2, 285.21, 285.22, 285.29, 285.8, 285.9
Transfusion	V58.2, 99.03, 99.04
Anemia	
<i>Neutropenia</i>	
Neutropenia and white blood cell disorders	288.0 288.00, 288.03, 288.09, 288.8 288.9
<i>Thrombocytopenia</i>	
Thrombocytopenia	287.4, 287.5
Platelet transfusion	99.05
<i>Venous Thromboembolism</i>	
DVT	453.4, 453.40, 453.41, 453.42, 453.89, 453.9, 453.8
PE	415.1, 415.11, 415.12, 415.13 415.19, v12.51
Thrombophlebitis-deep veins	451.1, 451.11, 451.19, 451.2, 451.8, 451.81, 451.83, 451.84, 451.89, 451.9
<i>Infection</i>	

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Bacteremia/sepsis	0.38.x, 790.7
Pneumonia	480.x, 481.x, 482.x, 483.x, 485, 486, 478.997.31
Shock	785.50, 785.51, 785.59, 458.0, 458.9, 958.4
Abscess	566, 567.22, 567.31, 567.38, 569.5, 682.9, 998.59
Urinary tract infection/pyelonephritis	590.x, 590.8x, 590.9, 595.0, 595.4, 595.889, 595.9, 599.0
Bronchitis	490
Influenza	487, 487.0, 487.1, 487.8
Cellulitis	681.x, 682.x
Empyema	510, 510.0, 510.9
Lung abscess	513, 513.0, 513.1
Fever	780.6

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Page 3 of 7

Appendix 2. Number of Infusions of Intraperitoneally Administered Chemotherapy

Intraperitoneal infusions	N	(%)
1	111	(12.9)
2	76	(8.9)
3	57	(6.6)
4	82	(9.6)
5	85	(9.9)
6	94	(10.9)
7	37	(4.3)
8	47	(5.5)
9	39	(4.5)
10	67	(7.8)
11	55	(6.4)
12	100	(11.6)
13	5	(0.6)
14	2	(0.2)
15	1	(0.1)
16	1	(0.1)

Each infusion represents a single drug administration; for commonly used IP regimens, 1 cycle of IP chemotherapy includes 2 infusions of intraperitoneal chemotherapy (1 each of cisplatin and paclitaxel).

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Page 4 of 7

Appendix 3. Distribution of Individual Complications Stratified by Type of Chemotherapy Received

	Standard		Intraperitoneal		Dose Dense		<i>P-value</i>
	N	%	N	%	N	%	
<i>Individual complications</i>							
<i>Electrolyte disorders</i>	478	(11.6)	195	(22.7)	116	(12.9)	<0.001
Hyponatremia	104	(2.5)	36	(4.2)	26	(2.9)	0.03
Hypokalemia	189	(4.6)	101	(11.8)	52	(5.8)	<0.001
Electrolyte disorder NOS	16	(0.4)	9	(1.1)	6	(0.7)	0.04
Infusion of electrolytes	10	(0.2)	7	(0.8)	1	(0.1)	0.01
Dehydration/hypovolemia	293	(7.1)	119	(13.9)	67	(7.5)	<0.001
Hypomagnesemia	75	(1.8)	59	(6.9)	30	(3.3)	<0.001
<i>Constitutional symptoms</i>	349	(8.4)	100	(11.6)	79	(8.8)	0.01
Malaise/fatigue/failure to thrive	155	(3.8)	41	(4.8)	40	(4.5)	0.29
Syncope	115	(2.8)	45	(5.2)	23	(2.6)	<0.001
Dizziness	72	(1.7)	17	(2.0)	13	(1.5)	0.69
Dysequilibrium	3	(0.1)	0	(0.0)	0	(0.0)	0.53
Adverse effects of systemic treatment	29	(0.7)	11	(1.3)	8	(0.9)	0.22
Complications of treatment	32	(0.8)	7	(0.8)	6	(0.7)	0.93
Signs or symptoms with or without chief complaint	13	(0.3)	4	(0.5)	2	(0.2)	0.66
<i>Gastrointestinal disorders</i>	548	(13.3)	212	(24.7)	123	(13.7)	<0.001
Nausea & emesis	381	(9.2)	160	(18.6)	82	(9.1)	<0.001
Diarrhea	135	(3.3)	51	(5.9)	23	(2.6)	<0.001
Constipation	152	(3.7)	50	(5.8)	35	(3.9)	0.01
Gastroenteritis/enteritis	53	(1.3)	9	(1.1)	14	(1.6)	0.63
<i>Malnutrition</i>	180	(4.4)	56	(6.5)	53	(5.9)	0.01
Failure to thrive	16	(0.4)	3	(0.4)	4	(0.5)	0.95

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Abnormal weight loss/underweight	11	(0.3)	2	(0.2)	1	(0.1)	0.69
Cachexia/Anorexia	25	(0.6)	6	(0.7)	6	(0.7)	0.94
Malnutrition	67	(1.6)	15	(1.8)	27	(3.0)	0.02
Parenteral nutrition/TPN/PPN	52	(1.3)	8	(0.9)	18	(2.0)	0.11
Nutritional/metabolic disorder	61	(1.5)	30	(3.5)	13	(1.5)	<0.001
<i>Anemia & red cell transfusion</i>	448	(10.8)	133	(15.5)	126	(14.0)	<0.001
Iron Deficiency anemia	33	(0.8)	8	(0.9)	8	(0.9)	0.91
Other deficiency anemia	11	(0.3)	2	(0.2)	4	(0.5)	0.63
Aplastic anemia	41	(1.0)	5	(0.6)	5	(0.6)	0.28
Other & unspecified anemia	336	(8.1)	97	(11.3)	96	(10.7)	0.002
Transfusion	199	(4.8)	65	(7.6)	58	(6.5)	0.002
<i>Neutropenia</i>	205	(5.0)	67	(7.8)	43	(4.8)	0.002
<i>Thrombocytopenia</i>	82	(2.0)	18	(2.1)	16	(1.8)	0.89
Thrombocytopenia	75	(1.8)	15	(1.8)	15	(1.7)	0.95
Platelet transfusion	18	(0.4)	3	(0.4)	5	(0.6)	0.80
<i>Venous thromboembolism</i>	208	(5.0)	72	(8.4)	51	(5.7)	<0.001
Deep vein thrombosis	108	(2.6)	31	(3.6)	29	(3.2)	0.21
Pulmonary embolism	131	(3.2)	50	(5.8)	30	(3.3)	<0.001
Thrombophlebitis-deep veins	24	(0.6)	9	(1.1)	5	(0.6)	0.28
<i>Infection</i>	636	(15.4)	162	(18.9)	138	(15.4)	0.04
Bacteremia/sepsis	132	(3.2)	36	(4.2)	30	(3.3)	0.34
Pneumonia	93	(2.3)	20	(2.3)	25	(2.8)	0.63
Shock	84	(2.0)	24	(2.8)	19	(2.1)	0.37
Abscess	231	(5.6)	46	(5.4)	40	(4.5)	0.39
Urinary tract infection/pyelonephritis	254	(6.1)	65	(7.6)	57	(6.4)	0.30
Bronchitis	11	(0.3)	3	(0.4)	3	(0.3)	0.88

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Influenza	7	(0.2)	1	(0.1)	1	(0.1)	0.88
Cellulitis	159	(3.9)	35	(4.1)	24	(2.7)	0.20
Empyema	4	(0.1)	1	(0.1)	1	(0.1)	0.98
Lung abscess	1	(0.0)	0	(0.0)	0	(0.0)	0.81
Fever	12	(0.3)	2	(0.2)	4	(0.5)	0.68

Outcomes were compared using χ^2 tests.

Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, et al. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. *Obstet Gynecol* 2016;127.

The authors provided this information as a supplement to their article.

Copyright © 2016 American College of Obstetricians and Gynecologists.

Page 7 of 7